'The Top Line': The initial reactions to Biogen's new CEO, plus this week's headlines

Biogen recently named Christopher Viehbacher its new CEO, ending a monthslong search to replace Michel Vounatsos. Fraiser Kansteiner and Kevin Dunleavy talk about the current state of the company and recent investor reactions to the new hire. Plus, they discuss a string of other biopharma CEO appointments. 

And, in this episode, we cover the week's news including what Albert Bourla, Ph.D., said that has him in hot water along with a $3.5 million drug, and we tease a possible major acquisition. 

To learn more about topics in this episode:

"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

To Listen to More Episodes from The Top Line